Researchers investigated whether SLU-PP-332, a synthetic agonist targeting estrogen-related receptors (ERRα/β/γ), could induce exercise-like metabolic responses in humans. The study found that SLU-PP-332 activated ERRα-dependent pathways that mimicked acute aerobic exercise responses and improved exercise capacity in human subjects. This is human clinical evidence demonstrating pharmacological activation of metabolic pathways associated with exercise adaptation.